在患有急性髓性白血病的患者中进行启动-克隆分析,这是继发于基本血小板血的急性髓性白血病
Yoko Ushijima1, Seara Naruse1, Yuichi Ishikawa2
1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Tsurumai-Cho 65, Showa-Ku, Nagoya, 466-8550, Japan.
Scientific reports
|July 10, 2024
概括
基本血小板血 (ET) 可以转化为急性髓性白血病 (AML). 这项研究揭示了JAK2未变异的克隆可以驱动AML转化,一个普通的克隆可以在某些患者中启动ET和AML.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 基本血小板血 (ET) 是一种骨髓增殖性瘤,通常是由JAK2,CALR或MPL突变驱动的.
- 转变为急性髓性白血病 (AML) 通常涉及这些克隆中获得额外的突变.
- 然而,在AML转化过程中,JAK2未变异的克隆也可以出现.
研究的目的:
- 为了研究从ET到AML的克隆进化.
- 确定驱动ET患者AML转变的特定克隆.
- 了解ET-AML转换中的三负克隆的起源.
主要方法:
- 分析了来自ET和AML阶段的8名患者的配对样本.
- 基因测序用于识别JAK2,CALR,MPL,TET2,TP53,SMARCC2,UBR4和ZNF143中的突变.
- 单细胞分类CD34+/CD38-分数,用于精确的克隆分析.
主要成果:
- 在最初患有JAK2突变ET的3名患者中,未发生JAK2突变的AML克隆增殖.
- 在两名患者中,TET2突变克隆被确定为ET和AML的潜在常见发起克隆.
- 在一个患有JAK2突变ET,SMARCC2,UBR4和ZNF143突变克隆的患者中,不是JAK2,在AML中增殖.
- 证据表明,JAK2突变ET和TP53突变AML的共同祖先克隆.
结论:
- 从ET到AML的克隆进化是复杂的,JAK2未变异的克隆有时会导致转变.
- 在某些情况下,一个共同的初始克隆可能是ET和随后的AML的基础.
- 需要进一步的研究来阐明SMARCC2,UBR4和ZNF143等新型突变在疾病进展中的作用.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
73
相关概念视频
Stem Cell Therapy for Tissue Regeneration
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Structure and Function of Leukocytes
An adult in good health typically has between 4,500 and 11,000 leukocytes, or white blood cells, per microliter of blood, which constitutes about 1% of the total blood volume. Unlike red blood cells, white blood cells contain a nucleus and other cellular organelles but do not have hemoglobin. Most white blood cells reside in connective tissues, particularly in lymphatic organs such as the lymph nodes, with only a small fraction present in circulating blood.
White blood cells protect the body...
White blood cells protect the body...
Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
